Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy

被引：0

作者：

Gillison, Maura L. ^{[1
]}

Blumenschein, George, Jr. ^{[2
]}

Fayette, Jerome ^{[3
]}

Guigay, Joel ^{[4
]}

Colevas, A. Dimitrios ^{[5
]}

Licitra, Lisa ^{[6
,7
]}

Harrington, Kevin J. ^{[8
]}

Kasper, Stefan ^{[9
]}

Vokes, Everett E. ^{[10
]}

Even, Caroline ^{[11
]}

Worden, Francis ^{[12
]}

Saba, Nabil F. ^{[13
]}

Iglesias Docampo, Lara Carmen ^{[14
]}

Haddad, Robert ^{[15
]}

Rordorf, Tamara ^{[16
]}

Kiyota, Naomi ^{[17
]}

Tahara, Makoto ^{[18
]}

Lynch, Mark ^{[19
]}

Kopit, Justin ^{[19
]}

Ferris, Robert L. ^{[20
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Ctr Leon Berard, Lyon, France

[4] FHU OncoAge, Ctr Antoine Lacassagne, Nice, France

[5] Stanford Univ, Stanford, CA 94305 USA

[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[7] Univ Milan, Milan, Italy

[8] Inst Canc Res, Royal Marsden NHS Fdn Trust, London, England

[9] Univ Hosp, West German Canc Ctr, Essen, Germany

[10] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[11] Gustave Roussy, Villejuif, France

[12] Univ Michigan, Ann Arbor, MI 48109 USA

[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[14] Hosp Univ 12 Octubre, Madrid, Spain

[15] Dana Farber Harvard Canc Ctr, Boston, MA USA

[16] Univ Spital Zurich, Zurich, Switzerland

[17] Kobe Univ Hosp, Kobe, Hyogo, Japan

[18] Hosp East, Natl Canc Ctr, Kashiwa, Chiba, Japan

[19] Bristol Myers Squibb, Princeton, NJ USA

[20] Univ Pittsburgh, Med Ctr, Ctr Canc, Pittsburgh, PA USA

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

215

引用

页码：144 / 144

页数：1

共 50 条

[21] Treatment beyond progression with nivolumab (nivo) in patients with recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the phase 3 CheckMate 141 study
Kasper, S.
Haddad, R.
Ferris, R. L.
Blumenschein, G., Jr.
Fayette, J.
Guigay, J.
Colevas, A. D.
Licitra, L.
Vokes, E. E.
Worden, F.
Saba, N. F.
Tahara, M.
Monga, M.
Lynch, M.
Zhu, J.
Shaw, J. W.
Gillison, M. L.
Harrington, K. J.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 250 - +
[22] Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and, neck (SCCHN) refractory to first-line platinum-based therapies.
Vermorken, JB
Bourhis, J
Trigo, J
Kies, M
Leon, X
Mueser, M
Amellal, N
Schueler, A
Baselga, J
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 501S - 501S
[23] Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups
Ferris, R. L.
Blumenschein, G. R.
Fayette, J.
Guigay, J.
Colevas, A. D.
Licitra, L.
Harrington, K.
Kasper, S.
Vokes, E. E.
Even, C.
Worden, F.
Saba, N. F.
Docampo, LCIglesias
Haddad, R. I.
Rordorf, T.
Kiyota, N.
Tahara, M.
Lynch, M.
Li, L.
Gillison, M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1317 - 1317
[24] Real-world outcomes for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab
Singh, P.
You, M.
Lubinga, S.
Zhang, Y.
ANNALS OF ONCOLOGY, 2019, 30
[25] EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAIN
Suarez, J.
Juarez-Garcia, A.
Shaw, J. W.
Contente, M.
Polanco, C.
VALUE IN HEALTH, 2018, 21 : S18 - S19
[26] A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients-The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group.
Even, Caroline
Daste, Amaury
Saada-Bouzid, Esma
Lefebvre, Gautier
Fayette, Jerome
Zanetta, Sylvie
Kaminsky, Marie-Christine
Cupissol, Didier
Prevost, Alain
Vauleon, Elodie
Johnson, Alison Claire
Salas, Sebastien
Rolland, Frederic
David, Miruna Timar
Jallut, Isabelle
Delaye, Jessy
Bourhis, Jean
Guigay, Joel
Texier, Matthieu
Auperin, Anne
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] PREDICTORS OF EFFICACY IN THE EXTREME STUDY: CETUXIMAB PLUS PLATINUM-BASED THERAPY FIRST-LINE IN PATIENTS WITH RECURRENT AND/OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
Vermorken, J. B.
Mesia, R.
Remenar, E.
Erfan, J.
Zabolotnyy, D.
Benasso, M.
Koralewski, P.
Gross, A.
Stroh, C.
Bokemeyer, C.
ANNALS OF ONCOLOGY, 2008, 19 : 217 - 217
[28] A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
Kim Cocks
Marta Contente
Sarah Simpson
Michael DeRosa
Fiona C. Taylor
James W. Shaw
PharmacoEconomics, 2019, 37 : 1041 - 1047
[29] A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
Cocks, Kim
Contente, Marta
Simpson, Sarah
DeRosa, Michael
Taylor, Fiona C.
Shaw, James W.
PHARMACOECONOMICS, 2019, 37 (08) : 1041 - 1047
[30] Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Ferris, Robert L.
Licitra, Lisa
Fayette, Jerome
Even, Caroline
Blumenschein, George, Jr.
Harrington, Kevin J.
Guigay, Joel
Vokes, Everett E.
Saba, Nabil F.
Haddad, Robert
Ramkumar, Shanmugasundaram
Russell, Jeffery
Brossart, Peter
Tahara, Makoto
Colevas, A. Dimitrios
Concha-Benavente, Fernando
Lynch, Mark
Li, Li
Gillison, Maura L.
CLINICAL CANCER RESEARCH, 2019, 25 (17) : 5221 - 5230

← 1 2 3 4 5 →